Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.00 USD
Change Today +0.02 / 0.33%
Volume 110.4K
CERU On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

cerulean pharma inc (CERU) Snapshot

Open
$5.98
Previous Close
$5.98
Day High
$6.27
Day Low
$5.92
52 Week High
03/19/15 - $10.87
52 Week Low
08/5/14 - $3.35
Market Cap
157.3M
Average Volume 10 Days
250.0K
EPS TTM
--
Shares Outstanding
26.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CERULEAN PHARMA INC (CERU)

Related News

No related news articles were found.

cerulean pharma inc (CERU) Related Businessweek News

No Related Businessweek News Found

cerulean pharma inc (CERU) Details

Cerulean Pharma Inc., a clinical-stage company, develops nanopharmaceutical product candidates in the areas of oncology and other diseases in the United States. The company’s lead product candidate is CRLX101, a tumor targeted nanoparticle-drug conjugate (NDC), which is in Phase II clinical trials for the treatment of relapsed renal cell carcinoma and relapsed ovarian cancer; and in Phase Ib clinical trials for the treatment of neoadjuvant rectal cancer, as well as in Phase II clinical trials for other indications, such as gastric cancer and small cell lung cancer. It is also developing CRLX301, a platform-generated clinical candidate, which is in Phase I clinical development for the treatment of tumor-targeted NDC. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Cambridge, Massachusetts.

39 Employees
Last Reported Date: 04/7/15
Founded in 2005

cerulean pharma inc (CERU) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $432.6K
Senior Vice President of Finance & Administra...
Total Annual Compensation: $301.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $407.9K
Compensation as of Fiscal Year 2014.

cerulean pharma inc (CERU) Key Developments

Cerulean Announces Fast Track Designation Granted for CRLX101 in Metastatic Renal Cell Carcinoma

Cerulean Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Cerulean’s lead nanoparticle-drug conjugate, CRLX101, in combination with Avastin® (bevacizumab) for the treatment of metastatic renal cell carcinoma (mRCC) following progression through two or three prior lines of therapy. The FDA’s Fast Track Program is designed to facilitate the development and expedite the review of drugs that are intended to treat serious conditions and fulfill an unmet medical need. CRLX101 is currently being evaluated in combination with Avastin as a treatment of relapsed renal cell carcinoma in a randomized Phase 2 trial. CRLX101 is a dynamically tumor-targeted nanoparticle-drug conjugate (NDC) designed to concentrate in tumors and slowly release its anti-cancer payload, camptothecin, inside tumor cells. CRLX101 inhibits topoisomerase 1 (topo 1), which is involved in cellular replication, and hypoxia-inducible factor-1a (HIF-1a), which research suggests is a master regulator of cancer cell survival mechanisms thought to promote drug and radiation resistance. CRLX101 has shown activity in four different tumor types, both as monotherapy and in combination with other cancer treatments. CRLX101 is currently in Phase 2 clinical development and has been dosed in more than 250 patients and has Fast Track designation in combination with Avastin® in metastatic renal cell carcinoma.

Cerulean Pharma Preclinical Data Shows CRLX101 Investigational Drug Targets Breast Cancer Cells

Cerulean Pharma Inc. said preclinical data has been published that demonstrates its CRLX101 investigational drug targets breast cancer stem cells and impedes resistance to anti-angiogenic therapy in mouse models. The results of the study demonstrate that CRLX101blocks the HIF-1a mediated increase in cancer stem cells induced by Avastin in a triple-negative breast cancer xenograft mouse model and the combined effects of CRLX101 plus Avastin on cancer stem cells and bulk tumor cells resulted in significant tumor shrinkage and delayed recurrence.

Cerulean Pharma Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 05:00 PM

Cerulean Pharma Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 05:00 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Christopher D.T. Guiffre, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERU:US $6.00 USD +0.02

CERU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CERU.
View Industry Companies
 

Industry Analysis

CERU

Industry Average

Valuation CERU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,524.8x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,346.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERULEAN PHARMA INC, please visit www.ceruleanrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.